|
Age (years)
|
28
|
52.5 (22–75; 20.0)
|
|
Sex (female), n (%)
|
28
|
26 (92.9)
|
|
Weight (kg)
|
28
|
75.5 (50–105;24.3)
|
|
Disease duration (months)
|
28
|
31.5 (4–180)
|
|
Medication
|
|
Methotrexate, n (%)
|
28
|
16 (57.1)
|
|
Prednisolone, n (%)
|
28
|
23 (82.1)
|
|
Biologics naïve, n (%)
|
25a
|
15 (60.0)
|
|
Clinical parameters
|
|
DAS28 (CRP)
|
28
|
4.61 (2.65–6.49; 1.75)
|
|
Tender joint count (28-TJC)
|
28
|
7.0 (0–22;8.75)
|
|
Swollen joint count (28-SJC)
|
28
|
2.5 (0–9;4.0)
|
|
VAS patient (0–10 cm)
|
28
|
6.0 (2.4–10;3.0)
|
|
VAS physician (0–10 cm)
|
28
|
4.0 (1.9–8.5;1.7)
|
|
Morning stiffness (min.)
|
28
|
30 (0–240;63.75)
|
|
Laboratory parameters
|
|
ESR (mm/h)
|
28
|
27 (8–66;21.0)
|
|
CRP (mg/l)
|
27b
|
5.4 (0.3–52;17.4)
|
|
Fluorescence optical imagingc
|
|
P1
|
28
|
1.5 (0–16;9.25)
|
|
P2
|
28
|
19.5 (0–36;14.5)
|
|
P3
|
28
|
1.0 (0–20;3.75)
|
|
PVM
|
28
|
5 (0–27;6.25)
|
|
Musculoskeletal ultrasound (US7 Score)
|
|
GS US7 synovitis (range 0–39)
|
28
|
11 (4–22;8.25)
|
|
PD US7 synovitis (range 0–39)
|
28
|
2.0 (0–17;3.0)
|
|
GS US7 tenosynovitis (range 0–5)
|
28
|
0.5 (0–3;1.0)
|
|
PD US7 tenosynovitis (range 0–15)
|
28
|
0 (0–2;1.0)
|
